Leveraging AI for Better Outcomes Across Drug Development - with Patricio La Rosa of Bayer

Today’s guest is Patricio La Rosa, Head of End-to-End Decision Science at Seed Production Innovation in Bayer Crop Science. With over 20 years of experience developing AI and data science solutions across healthcare and agriculture, Patricio joins Emerj Managing Editor Matthew DeMello to explore how machine learning can drive better outcomes across the drug development lifecycle, from research design to clinical deployment. Patricio discusses how AI is optimizing early trial planning, improving participant engagement, and supporting ethical, human-centered decisions at scale. Drawing lessons from both agriculture and life sciences, he emphasizes the importance of connecting technical models with real-world workflows. The conversation also delves into key barriers to AI adoption in clinical settings, including behavioral friction, model transparency, and challenges in orchestrating decision-making across global teams. Patricio offers a grounded perspective on what it takes to move from experimentation to enterprise impact in AI-driven R&D. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj’s flagship ‘AI in Business’ podcast!

Today’s guest is Akhil Khunger, VP in Quantitative Analytics at Barclays. Akhil returns to the program to discuss the evolving role of customer-facing AI in financial services and how financial institutions are embedding safety and security measures directly into client-facing systems. He delves into the risks financial services face, such as prompt injection and model jailbreaking, and how firms are balancing user experience with necessary guardrails. Later, he and Emerj Managing Editor Matthew DeMello explore the challenges of building transparent, trustworthy, and resilient AI systems for the next generation of financial services, especially in light of growing regulatory expectations. This episode is sponsored by ActiveFence. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj’s flagship ‘AI in Business’ podcast!

Today’s guest is Brice Challamel, Head of AI products and Innovation at Moderna. With experience working across five continents, he brings a global perspective to driving AI adoption, innovation management, and measurable results in life sciences. Brice joins Emerj Managing Editor Matthew DeMello to explore how Moderna is embedding AI into both its tools and corporate culture to scale collaboration, accelerate product development, and improve regulatory outcomes. He breaks down how AI is augmenting human creativity, enhancing team decision-making, and supporting patient engagement efforts, while keeping human insight at the center of AI strategy. Brice also shares lessons from other industries to shed light on what’s ahead for AI in regulated sectors like life sciences, where the technology has the potential to improve operational efficiency, vaccine adoption, and broader public health outcomes. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj’s flagship ‘AI in Business’ podcast! This episode is sponsored by MSTRO. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

As enterprises double down on generative AI initiatives, the intersection of data security, privacy, and unstructured data is quickly becoming mission-critical. In this episode, Dimitri Sirota, Co-founder and CEO of BigID, joins the podcast to explore how AI transformation is reshaping enterprise data governance, security, and compliance—and why understanding your “crown jewel” data is essential to building trustworthy AI systems. Dimitri outlines the three major forces driving today’s enterprise data challenges: accelerated cloud migration, a rising tide of global data privacy regulations, and the explosion of generative AI tools that rely on sensitive, unstructured data. He explains how enterprises can gain visibility into their AI programs and the data fueling them, mitigate shadow AI risks, and prepare for the next wave of agentic systems by adopting zero-trust models and real-time monitoring strategies. This episode is sponsored by BigID. Learn how BigID helps enterprises govern AI, mitigate data risk, and stay compliant here.

Today’s guest is Damion Nero, Head of Data Science at Takeda Pharmaceuticals. With over 15 years of experience applying AI, machine learning, and real-world data to drug development and precision medicine, Damion joins Emerj Managing Editor Matthew DeMello to explore the evolving role of AI in drug development and supply chain management. He breaks down how AI is currently streamlining administrative and regulatory tasks, improving efficiency across clinical trials, and saving valuable time for healthcare professionals. Damion also discusses why broader, transformative supply chain efficiencies are still on the horizon, as AI continues to evolve and scale in the pharmaceutical industry. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj’s flagship ‘AI in Business’ podcast!

Today’s guest is Marie Flanagan, Director of Product Management in Digital Projects and Solutions at IQVIA, who joins us to explore the overlooked intersection of AI and safety workflows in life sciences. As the industry experiences an explosion in the volume and diversity of data—from social media and call centers to audio and video files—Marie outlines the mounting challenges for pharmacovigilance and the opportunities AI is unlocking for healthcare and life sciences leaders. Marie discusses how advancements in voice-to-text transcription and automation are helping safety teams manage massive datasets, pinpoint potential risks, and reallocate human resources toward high-value activities like signaling and benefit-risk management. She also shares insights into where human expertise remains essential, particularly in interpreting complex clinical contexts that AI alone cannot fully capture. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj’s flagship ‘AI in Business’ podcast!

Today’s guest is Akhil Khunger, VP of Quantitative Analytics at Barclays. Akhil joins us to explore how financial institutions are modernizing stress testing, risk modeling, and strategic planning through AI. Throughout the episode, Akhil discusses the evolving architecture of financial models — specifically how modular, decoupled processes can speed up regulatory compliance and empower faster decision-making. He outlines how AI-powered code generation and user-friendly APIs are enabling more targeted scenario analysis without compromising performance across large, complex portfolios. Later, we highlight how global teams are leveraging AI to reduce dependency on legacy tech stacks and streamline business planning across jurisdictions. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business’ podcast! This episode is sponsored by Automation Anywhere. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

Today’s guest is Raheel Retiwalla, Chief Strategy Officer at Productive Edge — a digital transformation consultancy focused on healthcare. Productive Edge works with payers, providers, and health tech firms to leverage AI, data, and modern platforms to streamline operations, cut costs, and improve outcomes. With two decades of experience in digital transformation and AI strategy across regulated industries, Raheel joins Emerj Managing Editor Matthew DeMello on the show today to explore the emerging role of agentic AI in enterprise healthcare. He unpacks what agentic AI is, how it differs from traditional models, and why it’s set to change how healthcare leaders think about workflows, orchestration, and automation. This episode is sponsored by Productive Edge. Learn how brands work with Emerj and explore media options at emerj.com/ad1.

On today’s episode, we’re joined by Shub Agarwal, author of Successful AI Product Creation: A 9-Step Framework available from Wiley and a professor of the University of Southern California teaching AI and Generative AI product management to graduate students. He is also Senior Vice President of Product Management for AI and Generative AI at U.S. Bank. Shub joins Emerj’s Managing Editor Matthew DeMello on the show today to offer his perspective on what responsible AI adoption truly looks like in a regulated environment - and why method matters more than models. With over 15 years of experience bringing enterprise-grade AI products to life, he explains why “AI is the new UX” - and what that means for the future of digital interaction in banking and beyond. He also dives into the nuances of responsible AI adoption - not as a buzzword but as a framework rooted in decades of data governance and enterprise rigor. The opinions that Shub expresses in today’s show are his own and do not reflect that of U.S. Bank, the University of Southern California, or their respective leadership. This episode is sponsored by Searce. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

In this episode of the AI in Business Podcast, Brett Kiley, Executive Director of Customer Experience and Client Solutions at CVS Health, joins us for a compelling discussion on the evolving landscape of customer interactions. With over two decades of experience, Brett shares how CVS navigates the challenges of personalization, efficiency, and seamless service across their retail, pharmacy, and health services divisions. To access Emerj’s frameworks for AI readiness, ROI, and strategy, visit Emerj Plus at emerj.com/p1.